Literature DB >> 11564559

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits.

B M Kessler1, D Tortorella, M Altun, A F Kisselev, E Fiebiger, B G Hekking, H L Ploegh, H S Overkleeft.   

Abstract

BACKGROUND: The 26S proteasome is responsible for most cytosolic proteolysis, and is an important protease in major histocompatibility complex class I-mediated antigen presentation. Constitutively expressed proteasomes from mammalian sources possess three distinct catalytically active species, beta1, beta2 and beta5, which are replaced in the gamma-interferon-inducible immunoproteasome by a different set of catalytic subunits, beta1i, beta2i and beta5i, respectively. Based on preferred cleavage of short fluorogenic peptide substrates, activities of the proteasome have been assigned to individual subunits and classified as 'chymotryptic-like' (beta5), 'tryptic-like' (beta2) and 'peptidyl-glutamyl peptide hydrolyzing' (beta1). Studies with protein substrates indicate a far more complicated, less strict cleavage preference. We reasoned that inhibitors of extended size would give insight into the extent of overlapping substrate specificity of the individual activities and subunits.
RESULTS: A new class of proteasome inhibitors, considerably extended in comparison with the commonly used fluorescent substrates and peptide-based inhibitors, has been prepared. Application of the safety catch resin allowed the generation of the target compounds using a solid phase protocol. Evaluation of the new compounds revealed a set of highly potent proteasome inhibitors that target all individual active subunits with comparable affinity, unlike the other inhibitors described to date. Modification of the most active compound, adamantane-acetyl-(6-aminohexanoyl)(3)-(leucinyl)(3)-vinyl-(methyl)-sulfone (AdaAhx(3)L(3)VS), itself capable of proteasome inhibition in living cells, afforded a new set of radio- and affinity labels.
CONCLUSIONS: N-terminal extension of peptide vinyl sulfones has a profound influence on both their efficiency and selectivity as proteasome inhibitors. Such extensions greatly enhance inhibition and largely obliterate selectivity towards the individual catalytic activities. We conclude that for the interaction with larger substrates, there appears to be less discrimination of different substrate sequences for the catalytic activities than is normally assumed based on the use of small peptide-based substrates and inhibitors. The compounds described here are readily accessible synthetically, and are more potent inhibitors in living cells than their shorter peptide vinyl sulfone counterparts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564559     DOI: 10.1016/s1074-5521(01)00069-2

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  44 in total

1.  α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

Authors:  Martina Bazzaro; Ravi K Anchoori; Mohana Krishna R Mudiam; Olga Issaenko; Srinivas Kumar; Balasubramanyam Karanam; Zhenhua Lin; Rachel Isaksson Vogel; Riccardo Gavioli; Federica Destro; Valeria Ferretti; Richard B S Roden; Saeed R Khan
Journal:  J Med Chem       Date:  2010-12-27       Impact factor: 7.446

2.  Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.

Authors:  Dietmar Steverding; Robert W Spackman; Howard J Royle; Robert J Glenn
Journal:  Parasitol Res       Date:  2004-12-01       Impact factor: 2.289

3.  Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS.

Authors:  Nan Li; Chi-Lin Kuo; Guillem Paniagua; Hans van den Elst; Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Mark Ruben; Eric van Genderen; Jacob Gubbens; Gilles P van Wezel; Herman S Overkleeft; Bogdan I Florea
Journal:  Nat Protoc       Date:  2013-05-23       Impact factor: 13.491

Review 4.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

Review 5.  Harnessing proteasome dynamics and allostery in drug design.

Authors:  Maria Gaczynska; Pawel A Osmulski
Journal:  Antioxid Redox Signal       Date:  2014-02-21       Impact factor: 8.401

6.  Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.

Authors:  Nadia Hedhli; Paulo Lizano; Chull Hong; Luke F Fritzky; Sunil K Dhar; Huasheng Liu; Yimin Tian; Shumin Gao; Kiran Madura; Stephen F Vatner; Christophe Depre
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-01       Impact factor: 4.733

7.  PI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells.

Authors:  Ian Hammond-Martel; Helen Pak; Helen Yu; Raphael Rouget; Andrew A Horwitz; Jeffrey D Parvin; Elliot A Drobetsky; El Bachir Affar
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

Review 8.  Activity-based imaging probes of the proteasome.

Authors:  Kimberly Cornish Carmony; Kyung Bo Kim
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

9.  Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators.

Authors:  Zhao Dang; Kathy Jung; Keduo Qian; Kuo-Hsiung Lee; Li Huang; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2012-08-15       Impact factor: 4.345

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.